Eyetech Pharmaceuticals
CompanyUnited States
Eyetech Pharmaceuticals develops one asset, in phase 3, no development reported (pegaptanib sodium in age-related macular degeneration). Mostly oligonucleotide acting on VEGFA; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3, no development reported
- 1
- Trial
- 1
- Signal
Pipeline
1RNA aptamer antagonist that selectively binds and inhibits vascular endothelial growth factor 165 (VEGF165).
Phase 3, no development reported, Oligonucleotide, VEGFA, age-related macular degeneration
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6